Tyler Van Buren
Stock Analyst at TD Cowen
(2.49)
# 2,479
Out of 5,090 analysts
60
Total ratings
48.98%
Success rate
1.58%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $2.69 | - | 1 | Dec 2, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $15 | $9.38 | +59.91% | 3 | Nov 5, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $31.12 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $34.82 | +14.88% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $72.93 | +30.26% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $120.83 | +3.45% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $35.81 | - | 1 | Jul 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | n/a | $43.68 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $21.50 | - | 2 | Dec 12, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $18.31 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $30.84 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $26.91 | +122.97% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $3.48 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.95 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $722.00 | +66.20% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $21.16 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $34.99 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $57.34 | -47.68% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $33.45 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $67.53 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $76.16 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.07 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $38.80 | +80.41% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.40 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.68 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $22.27 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $13.00 | +1,630.77% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $9.91 | +8,729.47% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $17.97 | +122.59% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $18.72 | +60.26% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.26 | +3,868.25% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.29 | +811.85% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $4.22 | +4,644.96% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.88 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $28.17 | - | 1 | Aug 4, 2017 |
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $2.69
Upside: -
Biohaven
Nov 5, 2025
Maintains: Buy
Price Target: $50 → $15
Current: $9.38
Upside: +59.91%
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $31.12
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $34.82
Upside: +14.88%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $72.93
Upside: +30.26%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $120.83
Upside: +3.45%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $35.81
Upside: -
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $43.68
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $21.50
Upside: -
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $18.31
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $30.84
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $26.91
Upside: +122.97%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $3.48
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $6.95
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $722.00
Upside: +66.20%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $21.16
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $34.99
Upside: -
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $57.34
Upside: -47.68%
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $33.45
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $67.53
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $76.16
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.07
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $38.80
Upside: +80.41%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.40
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.68
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $22.27
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $13.00
Upside: +1,630.77%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $9.91
Upside: +8,729.47%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $17.97
Upside: +122.59%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $18.72
Upside: +60.26%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.26
Upside: +3,868.25%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $3.29
Upside: +811.85%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $4.22
Upside: +4,644.96%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $10.88
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $28.17
Upside: -